

CHARTERED ACCOUNTANTS

Independent Auditors' Review Report To The Board of Directors of Morepen Laboratories Limited

1. We have reviewed the accompanying statement of unaudited financial results of Morepen Laboratories Limited, ("the company") for the quarter and six months ended 30th September, 2014 ("the Statement") being submitted by the Company pursuant to the requirement of Clause 41 of the Listing Agreements with the Stock Exchanges, except for the disclosures regarding "Particulars of Shareholding" and "Investors Complaints" made by the management. We have also reviewed Statement of Assets and Liabilities of the company as on that date. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited financial results prepared in accordance with applicable accounting standards issued under the Companies (Accounting Standards) Rules, 2006 as required in terms of Section 133 of the Companies Act, 2013, read with Rule 7 of Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Kamal Mahajan And Co.
Chartered Accountants
(Firm Regn No. 006855N)

M. K. Mahajan

M. K. Mahajan
Partner

M. No. 017418 NEW DELHI



Place : New Delhi
Date : 13.11.2014


Morepen Laboratories Limited
Statement of Unaudited Financial Results
For the Quarter ended 30th September, 2014

(Rs.in Lacs)

Particulars	Standalone					
	Quarter Ended			Half Year Ended		Year Ended
	30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014
	(Unaudited)			(Unaudited)		(Audited)
1(a) Net Sales/Income from Operations (Net of Excise Duty)	8740.17	8643.74	7287.67	17383.91	15135.55	32206.37
(b) Other Operating Income	377.98	497.62	613.37	875.60	739.50	1390.31
Total Income from Operations (Net)	9118.15	9141.36	7901.04	18259.51	15875.05	33596.68
2 Expenditure						
a) Cost of Material Consumed	3636.54	3539.30	2857.34	7175.84	6360.04	13098.58
b) Purchase of stock - in - trade	2218.51	1840.58	1483.45	4059.09	2902.78	6791.48
c) Changes in inventories of Finished goods, Work -in- progress and Stock-in-trade	(45.37)	121.84	50.38	76.47	(177.49)	161.49
d) Employee benefits expenses	1094.92	1001.85	1029.22	2096.77	2001.24	3967.77
e) Depreciation and Amortisation	813.62	1100.27	1157.35	1913.89	2300.32	4576.72
f) Power and Fuel	200.29	214.32	231.76	414.61	453.78	841.68
g) Travelling Expenses	138.47	145.62	152.65	284.09	295.72	634.87
h) Selling and Distribution Expenses	312.75	439.92	359.52	752.67	691.22	1511.49
i) Other Expenses	527.20	423.01	493.27	950.21	942.47	2008.53
Total Expenditure	8896.93	8826.71	7814.94	17723.64	15770.08	33592.61
3 Profit / (Loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	221.23	314.65	86.10	535.88	104.97	4.07
4 Other Income / (Loss)	19.30	18.51	25.07	37.81	51.95	78.58
5 Profit / (Loss) from Ordinary activities before Finance Cost and Exceptional Items (3+4)	240.53	333.16	111.17	573.69	156.92	82.65
6 Finance Cost	201.78	204.86	238.91	406.64	518.14	988.93
7 Profit / (Loss) from Ordinary activities after Finance Cost but before Exceptional Items (5-6)	38.75	128.30	(127.74)	167.05	(361.22)	(906.28)
8 Exceptional Items - Income/(Expense)	-	-	-	-	-	-
9 Profit / (Loss) from Ordinary Activities before Tax (7-8)	38.75	128.30	(127.74)	167.05	(361.22)	(906.28)
10 Tax Expense	7.75	25.67	-	33.42	-	-
11 Profit / (Loss) from Ordinary Activities after Tax (9-10)	31.00	102.63	(127.74)	133.63	(361.22)	(906.28)
12 Extraordinary Items-Income/(Expense)	-	-	-	-	290.27	290.27
13 Net Profit / (Loss) for the period (11+12)	31.00	102.63	(127.74)	133.63	(70.95)	(616.01)
14 Paid-up Equity Share Capital of Face Value of Rs.2/- each	8995.86	8995.86	8995.86	8995.86	8995.86	8995.86
15 Reserves excluding Revaluation reserves	-	-	-	-	-	11464.88
16 a) Earning Per Share before Extraordinary Items (in Rs.) * Basic & Diluted	0.004	0.02	(0.03)	0.02	(0.09)	(0.21)
b) Earning Per Share after Extraordinary Items (in Rs.) * Basic & Diluted	0.004	0.02	(0.03)	0.02	(0.02)	(0.15)
A PARTICULARS OF EQUITY SHAREHOLDING						
1 Public Shareholding						
- Number of Shares	294454615	294454615	294454615	294454615	294454615	294454615
- Percentage of shareholding	65.46%	65.46%	65.46%	65.46%	65.46%	65.46%
2 Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered						
- Number of Shares	610000	610000	610000	610000	610000	610000
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.39%	0.39%	0.39%	0.39%	0.39%	0.39%
- Percentage of shares (as a % of the total share capital of the company)	0.14%	0.14%	0.14%	0.14%	0.14%	0.14%
b) Non-encumbered						
- Number of Shares	154761588	154761588	154761588	154761588	154761588	154761588
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	99.61%	99.61%	99.61%	99.61%	99.61%	99.61%
- Percentage of shares (as a % of the total share capital of the company)	34.40%	34.40%	34.40%	34.40%	34.40%	34.40%
B INVESTOR COMPLAINTS						
				For the Quarter ended 30th September, 2014		
Pending at the beginning of the quarter				Nil		
Received during the quarter				07		
Disposed off during the quarter				07		
Remaining unresolved at the end of the quarter				Nil		

*After considering dividend on preference shares.

Notes :



- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13th Nov 2014. A Limited review of the same had been carried out by the statutory auditors.
- The Company is exclusively engaged in the Pharmaceutical Business Segment.
- Consolidated Income from Operations, Net Profit, EPS for the quarter ended 30th Sep, 2014 stands at Rs.9993.29 Lacs, Rs.80.12 Lacs, & Rs.0.02 respectively.
- During the period, the Company has revised depreciation rates on certain fixed assets as per the useful life specified in the Companies Act, 2013 or as re-assessed by the company. Based on current assessment, depreciation of Rs. 1196.09 Lacs on the assets whose useful life is already exhausted as on 01/04/2014 have been adjusted to General Reserve. Had there not been any change in useful life of assets, depreciation for the quarter and six months ended would have been higher by Rs. 225.04 Lacs and Rs. 162.19 lacs respectively.
- Statement of Assets and Liabilities:

Particulars	Rs.in Lac	
	As at	As at
	30.09.2014 (Unaudited)	31.03.2014 (Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' Funds		
(a) Share Capital	20961.07	20961.07
(b) Reserves and Surplus	10402.35	11464.88
Shareholders' Funds	31363.42	32425.95
2 Non - Current Liabilities		
(a) Long term borrowings	6841.49	7464.97
(b) Other Long term liabilities	178.80	205.32
(c) Long term provisions	764.07	734.53
Non- current liabilities	7784.36	8404.82
3 Current Liabilities		
(a) Short term borrowings	335.80	118.56
(b) Trade Payables	7858.61	6675.36
(c) Other current liabilities	3143.53	3091.24
(d) Short term provisions	116.99	73.15
Current liabilities	11454.93	9958.31
TOTAL EQUITY AND LIABILITIES	50602.71	50789.08
B ASSETS		
1 Non Current Assets		
(a) Tangible Assets	25960.71	28888.19
(b) Intangible Assets	59.26	59.25
(c) Non - current Investments	11794.37	11794.02
(d) Long term loans and advances	174.43	175.03
Non- current assets	37988.77	40916.49
2 Current Assets		
(a) Inventories	3174.44	3290.92
(b) Trade receivables	6076.09	4008.55
(c) Cash and cash equivalents	614.19	807.31
(d) Short term loans and advances	2490.74	1406.51
(e) Other current assets	258.48	359.30
Current assets	12613.94	9872.59
TOTAL ASSETS	50602.71	50789.08

For and on behalf of the Board

Place : New Delhi
Date : 13-Nov-2014



Chairman & Managing Director

